Baidu
map

JCO:急性淋巴细胞白血病患者的脑脊液检查对预后影响重大

2017-05-26 MedSci MedSci原创

为了在确诊为急性淋巴细胞白血病(ALL)的患者中确定脑脊液(CSF)样品中的原始细胞、白细胞及红细胞的预后意义,研究人员进行了本研究,其中脑脊液和风险分类模式来自儿童肿瘤学组的急性B淋巴细胞白血病(B-ALL)临床试验。研究中脑脊液状态被设定如下:CNS1,没有原始细胞;CNS2a-2C,<5个白细胞/μL和有原始细胞及有/无≥10个红细胞/μL或≥5个白细胞/μL加原始细胞,同时白细胞数目是红细

为了在确诊为急性淋巴细胞白血病(ALL)的患者中确定脑脊液(CSF)样品中的原始细胞、白细胞及红细胞的预后意义,研究人员进行了本研究,其中脑脊液和风险分类模式来自儿童肿瘤学组的急性B淋巴细胞白血病(B-ALL)临床试验。

研究中脑脊液状态被设定如下:CNS1,没有原始细胞;CNS2a-2C,<5个白细胞/μL和有原始细胞及有/无≥10个红细胞/μL或≥5个白细胞/μL加原始细胞,同时白细胞数目是红细胞数目的5倍及以上;CNS3a-3C,≥5个白细胞/μL和有原始细胞及有/无≥10个红细胞/μL或中枢神经系统疾病的临床症状。CNS2状态不影响治疗;处于CNS3状态的患者在头颅放射18Cy诱导和增强治疗中接受两个额外的鞘内治疗。

研究人员共对2004年到2010年间8379例患者的结果进行了分析发现:7395例(88.3%)处于CNS1状态;857(10.2%)例处于CNS2状态;和127(1.5%)例处于CNS3状态。5年无事件生存率和总生存率分别为:CNSI组85%和92.7%,CNS2组76%和86.8%,CNS3组76%和82.1%(P<0.001)。对年龄、种族/民族、初始白细胞及第29天的微小残留白血病<0.1%、CSF原始细胞,忽略细胞计数的多变量分析发现,根据国家癌症研究所的标准,他们是标准或高风险患者预后不良的独立预测因子。EFS的差异反映了处于CNS1 vs CNS2和/或CNS3状态的患者的复发不是在骨骼而是在CNS。

研究人员认为低水平的中枢神经系统白血病,无论脑脊液中是否存在红细胞,其预后均较差,且中枢神经系统复发率较高。这些数据表明,对CNS2疾病患者额外增加CNS导向治疗是必要的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997834, encodeId=2dfb199e834d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 27 15:03:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891360, encodeId=acfc189136088, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 27 09:03:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203925, encodeId=43b420392500, content=。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/zJdmw9z0bAJicicnfs2fZyxljU8Gu8pl9bj0Tnv3o24WZudbEGOhTp1HjFFP8abUo61vTBcdX7gLeka0Yy0wPWhg/132, createdBy=72421968032, createdName=Eradicate, createdTime=Mon May 29 08:36:20 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302060, encodeId=616c130206087, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun May 28 02:03:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203153, encodeId=5120203153bb, content=好的诊疗常规,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 27 08:52:46 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997834, encodeId=2dfb199e834d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 27 15:03:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891360, encodeId=acfc189136088, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 27 09:03:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203925, encodeId=43b420392500, content=。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/zJdmw9z0bAJicicnfs2fZyxljU8Gu8pl9bj0Tnv3o24WZudbEGOhTp1HjFFP8abUo61vTBcdX7gLeka0Yy0wPWhg/132, createdBy=72421968032, createdName=Eradicate, createdTime=Mon May 29 08:36:20 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302060, encodeId=616c130206087, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun May 28 02:03:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203153, encodeId=5120203153bb, content=好的诊疗常规,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 27 08:52:46 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-08-27 lidong40
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997834, encodeId=2dfb199e834d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 27 15:03:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891360, encodeId=acfc189136088, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 27 09:03:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203925, encodeId=43b420392500, content=。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/zJdmw9z0bAJicicnfs2fZyxljU8Gu8pl9bj0Tnv3o24WZudbEGOhTp1HjFFP8abUo61vTBcdX7gLeka0Yy0wPWhg/132, createdBy=72421968032, createdName=Eradicate, createdTime=Mon May 29 08:36:20 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302060, encodeId=616c130206087, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun May 28 02:03:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203153, encodeId=5120203153bb, content=好的诊疗常规,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 27 08:52:46 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-29 Eradicate

    。。。。。。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1997834, encodeId=2dfb199e834d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 27 15:03:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891360, encodeId=acfc189136088, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 27 09:03:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203925, encodeId=43b420392500, content=。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/zJdmw9z0bAJicicnfs2fZyxljU8Gu8pl9bj0Tnv3o24WZudbEGOhTp1HjFFP8abUo61vTBcdX7gLeka0Yy0wPWhg/132, createdBy=72421968032, createdName=Eradicate, createdTime=Mon May 29 08:36:20 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302060, encodeId=616c130206087, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun May 28 02:03:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203153, encodeId=5120203153bb, content=好的诊疗常规,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 27 08:52:46 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997834, encodeId=2dfb199e834d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Jun 27 15:03:00 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891360, encodeId=acfc189136088, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 27 09:03:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203925, encodeId=43b420392500, content=。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/zJdmw9z0bAJicicnfs2fZyxljU8Gu8pl9bj0Tnv3o24WZudbEGOhTp1HjFFP8abUo61vTBcdX7gLeka0Yy0wPWhg/132, createdBy=72421968032, createdName=Eradicate, createdTime=Mon May 29 08:36:20 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302060, encodeId=616c130206087, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun May 28 02:03:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203153, encodeId=5120203153bb, content=好的诊疗常规,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 27 08:52:46 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-27 日月生辉

    好的诊疗常规,学习了

    0

相关资讯

INT J LAB HEMATOL:利用融合转录物对儿童B淋巴细胞白血病进行诊断

导致融合基因ETV6-RUNX1的转座易位t(12; 21)(p13; q22)是儿童B淋巴细胞白血病中最常见的基因融合。在北欧小儿血液学和肿瘤学ALL-2008治疗方案中,B系ALL中的治疗分层是在使用荧光激活细胞分选(FACS)的最小残留病(MRD)分析的结果上进行的。在本研究中,研究人员通过实验确定ETV6-RUNX1融合转录物的RT-qPCR是否是MRD分析的可靠替代方案。

2015培门冬酶治疗急性淋巴细胞白血病和恶性淋巴瘤中国专家共识发布

淋巴造血组织恶性肿瘤中急性淋巴细胞白血病(acutelymphoblasticleukemia,ALL)、淋巴母细胞淋巴瘤(lymphoblasticlymphoma,LBL)和NK/T细胞淋巴瘤是常见类型之一。 ALL和LBL是同一疾病在不同阶段的表现。ALL在青少年和儿童中发病率较高,占15岁以下儿童白血病的76%及所有儿童恶性肿瘤的35%。近年来恶性淋巴瘤的发病率也逐年上升,全国肿

STM:通用CAR-T成功治疗2例B细胞急性淋巴细胞白血病

一项新的分析报告显示,两名诊断患有复发性儿童期癌症的婴儿,在用尽几乎所有其他治疗方案未能奏效的情况下,接受了使用基因工程改造的T细胞的首次人体实验治疗后,在长达10-16个月期间成功维持完全缓解状态。过去这种基于细胞的方法一直难以在幼儿中实施。 在美国所有儿科癌症病例中,高达25%案例属于B细胞急性淋巴细胞白血病(ALL)。目前临床的用于治疗1岁和10岁之间的儿童急性淋巴细胞白血病有几种选择,但

FDA批准又一通用型CAR-T疗法进入临床试验

近日,施维雅(Servier)、辉瑞(Pfizer)和法国生物技术公司 Cellectis 联合宣布,CAR-T细胞疗法UCART19的实验性新药申请(IND)已获得美国食品和药物管理局(FDA)的批准,可在美国开展人体临床试验,用于治疗复发/难治性急性淋巴细胞白血病(ALL)的适应症。UCART19是一种同种异体CAR-T细胞疗法,利用Cellectis公司(医谷注:2017年2月7日,Cell

2016NCCN临床实践指南:急性淋巴细胞白血病(2016.V2)发布

2016年9月,美国国家综合癌症网络(NCCN)发布了急性淋巴细胞白血病2016年第2版。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)

中华血液学杂志, 2016,37(10): 837-845中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会白血病淋巴瘤学组成人急性淋巴细胞白血病(ALL)是最常见的成人急性白血病之一,约占成人急性白血病的20%~ 30%,目前国际上有比较统一的诊断标准和不同研究组报道的系统治疗方案,完全缓解(CR)率可达70%~90%,3~5年无病生存(DFS)率达30%~60%;美国癌症综合网(NCCN

Baidu
map
Baidu
map
Baidu
map